Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2020
SIETES contiene 93096 citas

 
 
<< anterior 21 a 40 de 826 siguiente >>
Presentar resultados
Seleccionar todas
21. Cita con resumen
Anónimo. Evolocumab (Repatha) - A second PCSK9 inhibitor to lower LDL-cholesterol. The Medical Letter on Drug and Therapeutics Bulletin 2015;57:140-1. [Ref.ID 99812]
22.Enlace a cita original Cita con resumen
Okuyama H, Langsjoen PH, Hamazaki T, Ogushi Y, Hama R, Kobayashi T, Uchino H. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Review of Clinical Pharmacology 2015;8:189-99. [Ref.ID 99700]
23. Cita con resumen
Burton BK, Balwani M, Feillet F, Varic I, Burrow TA, Grande CC, Coker M, Consuelo-Sánchez A, Deegan P, Di Rocco M, Enns GM, Erbe R, Ezgu F, Ficicioglu C, Nightingale S, Peters H, Scarpa M, Schwab O, Smolka V, Valayannopoulos V, Wood M, Goodman Z, Yang Y, Eckert S, Rojas-Caro S, Quinn AG. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. N Engl J Med 2015;373:1010-20. [Ref.ID 99532]
25. Cita con resumen
Hovingh GK, Kastelein JJP, van Deventer SJH, Round P, Ford J, Saleheen D, Rader DJ, Brewer HB, Barter PJ. Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipadaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2. Lancet 2015;386:452-60. [Ref.ID 99483]
26.Enlace a cita original Cita con resumen
Goulooze SC, Cohen AF, Rissmann R. Lomitapide. Br J Clin Pharmacol 2015;80:179-81. [Ref.ID 99474]
27.Tiene citas relacionadas Cita con resumen
Cainzos-Achirica M, Martin SS, Cornell JE, Mulrow CD, Guallar E. PCSK9 inhibitors: a new era in lipid-lowering treatment?. Ann Intern Med 2015;163:64-5. [Ref.ID 99337]
28.Tiene citas relacionadas Cita con resumen
Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry US, Lin Y, Brockmeyer M, Kandzari DE, Kubica JM, D'Agostino Sr RB, Kubica J, Volpe M, Agewall S, Kereiakes DJ. Effect of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Ann Intern Med 2015;163:40-51. [Ref.ID 99336]
29. Cita con resumen
30.Tiene citas relacionadas
Stone NJ, Lloyd-Jones DM. Lowering LDL cholesterol is good, but how and in whom?. N Engl J Med 2015;372:1564-5. [Ref.ID 99059]
31.Tiene citas relacionadas Cita con resumen
Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Med M, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA, for the Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9. [Ref.ID 99056]
32. Cita con resumen
Anónimo. Lomitapide. Prescrire 2015;35:168-71. [Ref.ID 98923]
33.
Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN. Statin-associated muscle symptoms: impact on statin therapy — European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management (CC) . Eur Heart J 2015;36:1012-22. [Ref.ID 98806]
34. Cita con resumen
Raal FJ, Honarpour N, Blom DJ, Hovingh GK, Scott R, Wasserman SM, Stein EA, for the TESLA Investigators. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:341-50. [Ref.ID 98743]
35. Cita con resumen
Raal FJ, Stein EA, Dufour R, Turner T, Civeira F, Burgess L, Langslet G, Scott R, Olsson AG, Sullivan D, Hovingh GK, Cariou B, Gouni-Berthold I, Somaratne R, Bridges I, Wasserman SM, Gaudet D, for the RUTHERFORD-2 Investigators. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. Lancet 2015;385:331-40. [Ref.ID 98742]
36. Cita con resumen
37. Cita con resumen
Gómez-Huelgas R, Martínez-Sellés M, Formiga F, Alemán Sánchez JJ, Camafort M, Galve E, Gil P, Lobos JM. Tratamiento de los factores de riesgo vascular en el paciente mayor de 80 años. Med Clin (Barc) 2014;143:134. [Ref.ID 97840]
38.Tiene citas relacionadas Cita con resumen
González-Molero I, Rojo G, Morcillo S, Pérez-Valero V, Rubio-Martín E, Gutiérrez-Repiso C, Soriguer F. Relación entre déficit de vitamina D y síndrome metabólico. Med Clin (Barc) 2014;142:473-7. [Ref.ID 97741]
39.Tiene citas relacionadas Cita con resumen
González-Parra E, Egido J. Vitamina D, síndrome metabólico y diabetes mellitus. Med Clin (Barc) 2014;142:493-6. [Ref.ID 97647]
40. Cita con resumen
Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Slein EA, for the DESCARTES Investigators. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809-19. [Ref.ID 97589]
Seleccionar todas
 
<< anterior 21 a 40 de 826 siguiente >>